Journal Mobile Options
Table of Contents
Vol. 22, No. 1, 2006
Issue release date: June 2006
Dement Geriatr Cogn Disord 2006;22:60–66
(DOI:10.1159/000093263)

The Effect of Apolipoprotein Polymorphism on Brain in Mild Cognitive Impairment: A Voxel-Based Morphometric Study

Pennanen C. · Testa C. · Boccardi M. · Laakso M.P. · Hallikainen M. · Helkala E.L. · Hänninen T. · Kivipelto M. · Könönen M. · Nissinen A. · Tervo S. · Vanhanen M. · Vanninen R. · Frisoni G.B. · Soininen H.
Departments of aNeurology and bClinical Radiology, Kuopio University Hospital, Departments of cNeuroscience and Neurology and dPublic Health, University of Kuopio, Kuopio, and eNational Institute of Public Health, Helsinki, Finland; fLaboratory of Epidemiology and Neuroimaging, IRCCS San Giovanni di Dio – FBF, Brescia, gAssociazione Fatebenefratelli per la Ricerca, Rome, and hMachine Vision Laboratory, Department of Mathematics and Computer Science, University of Udine, Udine, Italy

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

We investigated the effect of apolipoprotein E (ApoE) on the whole brain in 51 individuals with mild cognitive impairment using voxel-based morphometry. Between cases heterozygous for the ApoE ε4 (n = 15) and those who were ApoE ε4 noncarriers (n = 28), only the right parahippocampal gyrus, with the entorhinal cortex included, reached the level of statistical significance. In cases homozygous for the ε4 allele (n = 8) versus noncarriers, the greatest atrophy was located in the right amygdala followed by the right parahippocampal gyrus, the left amygdala and the left medial dorsal thalamic nucleus.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Saunders AM, Trowers MK, Shimkets RA, Blakemore S, Crowther DJ, Mansfield TA, Wallace DM, Strittmatter WJ, Roses AD: The role of apolipoprotein E in Alzheimer’s disease: pharmacogenomic target selection. Biochim Biophys Acta 2000;1502:85–94.
  2. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van Duijn CM: Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997;278:1349–1356.
  3. Alberts MS: Cognitive and neurobiologic markers of early Alzheimer disease. Proc Natl Acad Sci USA 1996;93:13547–13551.
  4. Engelborghs S, Dermaut B, Goeman J, Saerens J, Marien P, Pickut BA, Van den Broeck M, Serneels S, Cruts M, Van Broeckhoven C, De Deyn PP: Prospective Belgian study of neurodegenerative and vascular dementia: APOE genotype effects. J Neurol Neurosurg Psychiatry 2003;74:1148–1151.
  5. Lehtovirta M, Laakso MP, Frisoni GB, Soininen H: How does the apolipoprotein E genotype modulate the brain in aging and in Alzheimer’s disease? A review of neuroimaging studies. Neurobiol Aging 2000;21:293–300.
  6. Petersen RC, Smith GE, Ivnik RJ, Tangalos EG, Schaid DJ, Thibodeau SN, Kokmen E, Waring SC, Kurland LT: Apolipoprotein E status as a predictor of the development of Alzheimer’s disease in memory-impaired individuals. JAMA 1995;273:1274–1278.
  7. DeCarli C, Miller BL, Swan GE, Reed T, Wolf PA, Carmelli D: Cerebrovascular and brain morphologic correlates of mild cognitive impairment in the National Heart, Lung, and Blood Institute Twin Study. Arch Neurol 2001;58:643–647.
  8. Lopez OL, Jagust WJ, Dulberg C, Becker JT, DeKosky ST, Fitzpatrick A, Breitner J, Lyketsos C, Jones B, Kawas C, Carlson M, Kuller LH: Risk factors for mild cognitive impairment in the Cardiovascular Health Study Cognition Study. Part 2. Arch Neurol 2003;60:1394–1399.
  9. Tervo S, Kivipelto M, Hanninen T, Vanhanen M, Hallikainen M, Mannermaa A, Soininen H: Incidence and risk factors for mild cognitive impairment: a population-based three-year follow-up study of cognitively healthy elderly subjects. Dement Geriatr Cogn Disord 2004;17:196–203.
  10. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E: Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303–308.
  11. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST: Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1133–1142.
  12. Ashburner J, Csernansky JG, Davatzikos C, Fox NC, Frisoni GB, Thompson PM: Computer-assisted imaging to assess brain structure in healthy and diseased brains. Lancet Neurol 2003;2:79–88.
  13. Chételat G, Desgranges B, de la Sayette V, Viader F, Eustache F, Baron J-C: Mapping gray matter loss with voxel-based morphometry in mild cognitive impairment. Neuroreport 2002;13:1939–1943.
  14. Chételat G, Landeau B, Eustache F, Mezenge F, Viader F, de la Sayette V, Desgranges B, Baron J-C: Using voxel-based morphometry to map the structural changes associated with rapid conversion in MCI: a longitudinal MRI study. Neuroimage 2005;27:934–946.
  15. Pennanen C, Testa C, Laakso MP, Perrone MG, Hallikainen M, Helkala EL, Hänninen T, Kivipelto M, Könönen M, Nissinen A, Tuomainen S, Vanhanen M, Vanninen R, Frisoni GB, Soininen H: A voxel-based morphometry study on mild cognitive impairment. J Neurol Neurosurg Psychiatry 2005;76:11–14.
  16. Karas GB, Scheltens P, Rombouts SARB, Visser PJ, van Schijndel RA, Fox NC, Barkhof F: Global and local gray matter loss in mild cognitive impairment and Alzheimer’s disease. Neuroimage 2004;23:708–716.
  17. Bell-McGinty S, Lopez OL, Meltzer CC, Scanlon JM, Whyte EM, DeKosky ST, Becker JT: Differential cortical atrophy in subgroups of mild cognitive impairment. Arch Neurol 2005;62:1393–1397.
  18. Hänninen T, Hallikainen M, Tuomainen S, Vanhanen M, Soininen H: Prevalence of mild cognitive impairment: a population-based study in elderly subjects. Acta Neurol Scand 2002;106:148–154.
  19. Kivipelto M, Helkala E-L, Hänninen T, Laakso MP, Hallikainen M, Alhainen K, Soininen H, Tuomilehto J, Nissinen A: Midlife vascular risk factors and late-life mild cognitive impairment: a population-based study. Neurology2001;56:1683–1689.
  20. Pennanen C, Kivipelto M, Tuomainen S, Hartikainen P, Hänninen T, Laakso MP, Hallikainen M, Vanhanen M, Nissinen A, Helkala E-L, Vainio P, Vanninen R, Partanen K, Soininen H: Hippocampus and entorhinal cortex in mild cognitive impairment. Neurobiol Aging2004;25:303–310.
  21. Smith GE, Petersen RC, Parisi JE, Ivnik RJ, Kokmen E, Tangalos EG, Waring S: Definition, course, and outcome of mild cognitive impairment. Aging Neuropsychol Cogn 1996;3:141–147.

    External Resources

  22. Tsukamoto K, Watanabe T, Matsushima T, Kinoshita M, Kato H, Hashimoto Y, Kurokawa K, Teramoto T: Determination by PCR-RFLP of apo E genotype in a Japanese population. J Lab Clin Med 1993;121:598–602.
  23. Rorden C, Brett M: Stereotaxic display of brain lesions. Behav Neurol 2001;112:191–200.
  24. Good CD, Johnsrude IS, Ashburner J, Henson RN, Friston KJ, Frackowiak RS: A voxel-based morphometric study of ageing in 465 normal adult human brains. Neuroimage 2001;14:21–36.
  25. Evans AC, Kamber M, Collins DL, Macdonald D: An MRI-based probabilistic atlas of neuroanatomy; in Shorvon S, Fish D, Andermann F, et al (eds): Magnetic Resonance Scanning and Epilepsy. New York, Plenum Press, 1994, pp 263–274.
  26. Baron JC, Chételat G, Desgranges B, Perchey G, Landeau B, de la Sayette V, Eustache F: In vivo mapping of gray matter loss with voxel-based morphometry in mild Alzheimer’s disease. Neuroimage 2001;14:298–309.
  27. Ashburner J, Friston KJ: Why voxel-based morphometry should be used. Neuroimage 2001;14:1238–1243.
  28. Geroldi C, Pihlajamäki M, Laakso MP, DeCarli C, Beltramello A, Bianchetti A, Soininen H, Trabucchi M, Frisoni GB: ApoE ε4 is associated with less frontal and more medial temporal lobe atrophy in AD. Neurology 1999;53:1825–1832.
  29. Geroldi C, Laakso MP, DeCarli C, Beltramello A, Bianchetti A, Soininen H, Trabucchi M, Frisoni GB: Apolipoprotein E genotype and hippocampal asymmetry in Alzheimer’s disease: a volumetric MRI study. J Neurol Neurosurg Psychiatry 2000;68:93–96.
  30. Juottonen K, Lehtovirta M, Helisalmi S, Riekkinen PJ Sr, Soininen H: Major decrease in the volume of the entorhinal cortex in patients with Alzheimer’s disease carrying the apolipoprotein E ε4 allele. J Neurol Neurosurg Psychiatry 1998;65:322–327.
  31. Lehtovirta M, Soininen H, Laakso MP, Partanen K, Helisalmi S, Mannermaa A, Ryynanen R, Kuikka J, Hartikainen P, Riekkinen PJ Sr: SPECT and MRI analysis in Alzheimer’s disease: relation to apolipoprotein E ε4 allele. J Neurol Neurosurg Psychiatry 1996;60:644–649.
  32. Braak H, Braak E: Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239–259.
  33. Braak H, Braak E, Bohl J: Staging of Alzheimer-related cortical destruction. Eur Neurol 1993;33:403–408.
  34. Chen R, Herskovits EH: Network analysis of mild cognitive impairment. Neuroimage 2005;2006;29:1252–1259.

    External Resources

  35. Braak H, Braak E: Alzheimer’s disease affects limbic nuclei of the thalamus. Acta Neuropathol 1991;81:261–268.
  36. Jernigan TL, Salmon DP, Butters N, Hesselink JR: Cerebral structure on MRI. II. Specific changes in Alzheimer’s and Huntington’s diseases. Biol Psychiatry 1991;29:68–81.
  37. Karas GB, Burton EJ, Rombouts SA, van Schijndel RA, O’Brien JT, Scheltens P, McKeith IG, Williams D, Ballard C, Barkhof F: A comprehensive study of gray matter loss in patients with Alzheimer’s disease using optimized voxel-based morphometry. Neuroimage2003;18:895–907.
  38. Reiman EM, Caselli RJ, Chen K, Alexander GE, Bandy D, Frost J: Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: a foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer’s disease. Proc Natl Acad Sci USA 2001;98:3334–3339.
  39. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE: Metabolic reduction in the posterior cingulate cortex in very early Alzheimer’s disease. Ann Neurol 1997;42:85–94.
  40. Reiman EM, Caselli RJ, Yun LS, Chen K, Bandy D, Minoshima S, Thibodeau SN, Osborne D: Preclinical evidence of Alzheimer’s disease in persons homozygous for the ε4 allele for apolipoprotein E. N Engl J Med 1996;334:752–758.
  41. Desgranges B, Baron J-C, de la Sayette V, Petit-Taboue M-C, Landeau B, Eustache F: The neural substrates of memory systems impairment in Alzheimer’s disease – A PET study of resting brain glucose utilization. Brain 1998;121:611–631.
  42. Chételat G, Desgranges B, de la Sayette V, Viader F, Eustache F, Baron J-C: Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer’s disease? Neurology 2003;60:1374–1377.
  43. Nestor PJ, Fryer TD, Smielewski P, Hodges JR: Limbic hypometabolism in Alzheimer’s disease and mild cognitive impairment. Ann Neurol 2003;54:343–351.
  44. Nestor PJ, Scheltens P, Hodges JR: Advances in the early detection of Alzheimer’s disease. Nat Med 2004;10(suppl):S34–41.

    External Resources

  45. Cao Q, Jiang K, Liu Y, Zhang M, Xiao S, Zuo C, Huang H: The comparison of the regional cerebral metabolism rate of glucose in Alzheimer’s disease with mild cognitive impairment. Zhonghua Yi Xue Za Zhi 2002;82:1613–1616.

    External Resources

  46. Frisoni GB, Testa C, Zorzan A, Sabattoli F, Beltramello A, Soininen H, Laakso MP: Detection of gray matter loss in mild Alzheimer’s disease with voxel based morphometry. J Neurol Neurosurg Psychiatry 2002;73:657–664.
  47. Ohnishi T, Matsuda H, Tabira T, et al: Changes in brain morphology in Alzheimer disease and normal aging: is Alzheimer disease an exaggerated aging process? AJNR Am J Neuroradiol 2001;22:1680–1685.
  48. Rambouts SA, Barkhof F, Witter MP, Scheltens P: Unbiased whole-brain analysis of gray matter loss in Alzheimer’s disease. Neurosci Lett 2000;285:231–233.
  49. Soininen H, Partanen K, Pitkänen A, Hallikainen M, Hänninen T, Helisalmi S, Mannermaa A, Ryynänen M, Koivisto K, Riekkinen P Sr: Decreased hippocampal volume asymmetry on MRIs in nondemented elderly subjects carrying the apolipoprotein E ε4 allele. Neurology 1995;45:391–392.
  50. Tohgi H, Takahashi S, Kato E, Homma A, Niina R, Sasaki K, Yonezawa H, Sasaki M: Reduced size of right hippocampus in 39- to 80-year-old normal subjects carrying the apolipoprotein E ε4 allele. Neurosci Lett 1997;236:21–24.
  51. Lehtovirta M, Laakso MP, Soininen H, Helisalmi S, Mannermaa A, Helkala E-L, Partanen K, Ryynänen M, Vainio P, Hartikainen P, Riekkinen PJ Sr: Volumes of hippocampus, amygdala and frontal lobe in Alzheimer patients with different apolipoprotein E genotypes. Neuroscience 1995;67:65–72.
  52. Boccardi M, Sabattoli F, Testa C, Beltramello A, Soininen H, Frisoni GB: APOE modulation of Alzheimer’s and frontotemporal dementia. Neurosci Lett 2004;356:167–170.
  53. Boccardi M, Pennanen C, Laakso MP, Testa C, Geroldi C, Soininen H, Frisoni GB: Amygdaloid atrophy in frontotemporal dementia and Alzheimer’s disease. Neurosci Lett 2002;335:139–143.
  54. Cuénod CA, Denys A, Michot J-L, Jehenson P, Forette F, Kaplan D, Syrota A, Boller F: Amygdala atrophy in Alzheimer’s disease: an in vivo magnetic resonance imaging study. Arch Neurol 1993;50:941–945.
  55. Mann DMA: The neuropathology of the amygdala in ageing and in dementia; in Aggleton JP (ed): The Amygdala: Neurobiological Aspects of Emotion, Memory and Mental Dysfunction. New York, Wiley-Liss, 1992, pp 575–593.
  56. Scott SA, DeKosky ST, Scheff SW: Volumetric atrophy of the amygdala in Alzheimer’s disease: quantitative serial reconstruction. Neurology 1991;41:351–356.
  57. Vogt LJK, Human BT, Van Hoesen GW, Damasio AR: Pathological alterations in the amygdala in Alzheimer’s disease. Neuroscience 1990;37:377–385.
  58. Busatto GF, Garrido GEJ, Almeida OP, Castro CC, Camargo CHP, Cid CG, Buchpiguel CA, Furuie S, Bottino CM: A voxel-based morphometry study of temporal lobe gray matter reductions in Alzheimer’s disease. Neurobiol Aging 2003;24:221–231.
  59. Good CD, Scahill RI, Fox NC, Ashburner J, Friston KJ, Chan D, Crum WR, Rossor MN, Frackowiak RS: Automatic differentiation of anatomical patterns in the human brain: validation with studies of degenerative dementias. Neuroimage 2002;17:29–46.
  60. Larrieu S, Letenneur L, Orgogozo JM, Fabrigoule C, Amieva H, Le Carret N, Barberger-Gateau P, Dartigues JF: Incidence and outcome in mild cognitive impairment in a population-based prospective cohort. Neurology 2002;26;59:1594–1599.

    External Resources



Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50